Skip to content

Improving Patient Care with AdaptDx Pro

Earlier, More Accurate Detection

Structural changes (the appearance of drusen) in the retina are not always easily discernible. They often become evident only after AMD has progressed from a subclinical state.

Being able to identify the earliest AMD biomarker with such accuracy will help improve your patients’ outcomes. It allows you to detect AMD at the subclinical stage, at least three years before drusen are visible, when action can be taken to hopefully slow disease progression.

High-Touch Patient Care

The AdaptDx Pro also offers an optimal patient experience. The lightweight headset adapts to each patient, providing a personalized fit. A padded liner and adjustable strap enhance patient comfort. Plus, new Comfort Guard™ eyecup covers ensure a soft and clean surface for each patient.

Our friendly on-board technician, Theia™, guides patients through the test. Her personalized coaching increases the likelihood of consistent, reliable results. Powered by artificial intelligence, Theia delivers a uniform experience.

The AdaptDx Pro gives us the opportunity to change the future of macular degeneration care because it allows us to screen everyone at risk and identify macular degeneration earlier. The whole objective is to reduce the number of patients losing vision from macular degeneration.

RyanPowell Ryan Powell, OD View all testimonials

When the Diagnosis is AMD

Once you diagnose your patient with AMD, you can determine a course of action and start monitoring the patient more frequently. Treatment recommendations for all stages of AMD include:ii

  • Recommending smoking cessation programs
  • Prescribing nutritional supplementation
  • Discussing lifestyle modifications, such as diet and exercise
  • Managing systemic diseases with the patient’s primary care physician
  • Prescribing blue light protection, plus UVA and UVB sunglasses for outdoor protection

Monitoring Disease Progression

Functional testing and structural examinations may be useful for monitoring disease progression. More frequent visits increase your opportunity to detect choroidal neovascularization (CNV) before visual acuity loss. The follow-up interval may be shortened to every three or four months for patients who are progressing rapidly or are at high risk of CNV.

Improving Dark Adaptation Testing for Patients

With the AdaptDx Pro™, Dr. Ryan Powell and his staff at Insight Eyecare Specialties, Inc. are confident in their ability to provide convenient and comfortable dark adaptation testing for their patients.

adaptdxpro

Testing with AdaptDx Pro

See how your practice can use the AdaptDx Pro to help detect and monitor AMD.

Drive Practice Growth

Integrating AdaptDx Pro testing in your practice has the potential to drive medical revenue and attract new patients.

Implementation Expertise

Each AdaptDx Pro purchase is supported by our AMD Excellence Program®️ to help you achieve your patient care and practice growth goals.